LinkedIn post ESRR2024

📢 Important update on EU #GMP Annex 1 at #ESRR2024

The revised EU GMP Annex 1, effective since August 2023, has undergone a significant expansion, growing from 16 to a comprehensive 58 pages! 👉 Join the round table on GMP and Legislation featuring the expertise of Lars Perk — one of the three distinguished experts leading the discussion. He proposes to explore the new requirements, detailed insights, and an intensified focus on risk management and contamination control strategy. 

📚 He studied Chemistry at the University of Wageningen and obtained his PhD at the VUmc in Amsterdam. In 2008, he joined the BV Cyclotron of the VU in Amsterdam as R&D project manager. In this position, he was responsible for the development of new (mainly 18F) radiopharmaceuticals. He was also closely involved in the realization of a new manufacturing unit for radiopharmaceuticals for the VUmc. Since August 2013, he is Operational Manager at Radboud Translational Medicine (RTM). Since December 2016, he is Managing Director. He is also the coordinating radiation protection expert and Qualified Person at RTM. 

🔎Don’t miss the chance to participate and gain insights onto the impact of the revised Annex 1, attend the round table for an in-depth discussion: https://lnkd.in/d-QUaPMX

#Pharmaceuticals #Radiopharmaceuticals #RiskManagment #Innovation

LinkedIn post ESRR2024

Other news

18F-FDOPA now available

18F-FDOPA now available

Fluorodopa (18F) is now available for clinical studies and - with doctor's certificate - for routine...

Read more

GMP-certificate received

GMP-certificate received

Today we received our GMP-certificate!The results of the inspection were excellent and no shortcomin...

Read more

ABX has received marketing authorisation for the radiotracer Radelumin® in Germany

ABX has received marketing authorisation for the radiotracer Radelumin® in Germany

ABX has received marketing authorisation for the radiotracer Radelumin® in Germany! This marks the 8...

Read more

First Patient Dosed in Phase II Study of TLX250-CDx in Triple-Negative Breast Cancer

First Patient Dosed in Phase II Study of TLX250-CDx in Triple-Negative Breast Cancer

The below product is manufactured at RTM First Patient Dosed in Phase II Study of TLX250-CDx in Tri...

Read more

Interested in a collaboration?

Contact us to discuss the possibilities.